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Both obesity rates and antidepressant use have escalated in the last 20 years. Most people
who start antidepressant treatment discontinue it on their own. Meanwhile, obesity rates
continue to increase. To test the hypothesis that antidepressant use is a risk factor for obesity,
even after long-term discontinuation, we developed a novel animal paradigm consisting of
short-term exposure to stress and antidepressants, followed by long-term high-fat diet. We
show here that recurrent restraint stress (RRS)-related weight loss is recovered 2 weeks after
the end of stress in young growing rats receiving a high-fat diet. It is noteworthy that animals
that received short-term antidepressant treatment with either imipramine or fluoxetine during
7 days of RRS showed behavioral evidence of antidepressant effects. When exposed to a high-
fat diet after stress and when antidepressant treatment had ended, the animals had significant
increases in caloric intake, body weight (BW) and size from 17 to 22 weeks following
antidepressant discontinuation when compared with (control) RRS animals treated with saline
and fed with a high-fat diet. These data are consistent with the previously described
phenomenon of time-dependent sensitization, and support the notion that enduring effects of
short-term antidepressant treatment become manifest on a long-term basis after antidepres-
sant discontinuation, during conditions of high stress followed by high-fat intake. Analyses of
open field and body size measurements obtained in a small subset of animals show that
animals previously exposed to antidepressant had no deficits in locomotor activity and
were larger. Antidepressant exposure may therefore be a covert, insidious and enduring risk
factor for obesity, even after discontinuation of antidepressant treatment. Our data support
the concept of persistent, long-term effects of pharmacological–environment interactions on
BW regulation.
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Introduction
Major depressive disorder (MDD) is a serious public
health problem. Currently, the point prevalence of
MDD is B4–7%, and the lifetime prevalence estimate
ranges from 15 to 20%.
1,2 MDD is the leading cause of
disability measured in years lost because of disability,
and the largest single cause of nonfatal disease burden
in Australia.
3 It will become the second leading
contributor to global burden of disease by the year
2020 (disability-adjusted life year).
4 Approximately
59% of individuals with MDD seek help for their
condition, and 35% receive medication or psycholo-
gical treatment.
3 According to the Canadian Commu-
nity Health Survey, the prevalence of antidepressant
use over a period of 12 months between 2001 and
2002 was estimated at 5.8%.
5
MDD is a common complex disorder that affects
B121 million people worldwide. In the United
States, the economic burden of MDD is in the order
of $100 billions per year, with workplace costs being
the largest component.
6 Antidepressant dispensing
has increased substantially during the last two
decades in Western countries. In the United States,
antidepressants are prescribed to 27 million people
and they are the most frequently prescribed class of
medication.
7,8 In the United Kingdom, France and
Australia, antidepressant prescriptions have in-
creased substantially since the early 1990s with the
entry of selective serotonin reuptake inhibitors
(SSRIs) in the marketplace.
9–11
Studies examining weight gain during long-
term SSRI treatment have reported inconsistent
results. The results of a large, cross-sectional study
based on the General Electric Medical Records
Database of MDD patients treated with antidepressant
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in the proportion of patients who gained at least 7%
of their body weight (BW) during treatment. The
highest percentage of patients with weight gain was
associated with mirtazapine (26%), followed by the
SSRIs (16–19%).
12 Antidepressant treatment can be
effective in MDD, but compliance is low: in a large
European study of 7525 patients, 56% abandoned
treatment within 4 months.
13
It is generally accepted that the side effects such as
weight gain can adversely affect adherence to therapy,
but according to Bulloch and Patten,
5 the main reason
for non-adherence was forgetting (74.5% of respon-
ders), followed by ‘felt better’ (10.7%); side effects
were reported as the fourth reason (5.9%). It is
commonly stated that patients return to their previous
weight after they stop taking antidepressants, but this
assumption is not evidence based.
To complicate matters, clinical and animal weight
data during antidepressant treatment have been
difficult to integrate because they appear to support
divergent effects; a large body of studies have
supported that administration of several antidepres-
sants result in failure to gain weight or ‘paradoxical’
weight loss in rats, especially at high doses.
14,15
Consequently, animal paradigms that help close some
of these gaps could significantly expand our under-
standing of the interface between obesity and MDD.
There is a strong body of translational work that uses
rodents to study the biology of depression and
antidepressants. These studies have shown that a
mechanism of action of antidepressants is to promote
neurogenesis in the adult rat hippocampus.
16 Animal
models of depression have included stress paradigms
(such as uncontrollable stress, chronic mild stress and
repeated restraint stress (RRS)) that have been shown
to decrease cell proliferation in the hippocampus, and
administration of antidepressants can block this
downregulation of cell proliferation.
17
The use of antidepressants has grown dramatically
since the late 1980s with the advent of the selective
monoamine reuptake inhibitors.
27 Vast numbers
of people are exposed to antidepressants on a short-
term basis, as long-term compliance is not usually
achieved.
3,5 Such increased exposure to even short
courses of antidepressant drugs temporally coincides
with the emerging epidemic of obesity that is faced by
developed countries. Could the current dramatic
increase in obesity be attributed at least in part to
exposure to antidepressants? It has been previously
demonstrated that the effects of drugs may continue
to increase over time, even after a single dose and as
drug levels decrease: this intriguing phenomenon is
known as time-dependent sensitization (TDS).
18
We have hypothesized that TDS, which has been
described during short-term antidepressant treatment,
may apply to weight regulation after exposure to
antidepressants. To test this hypothesis, we devel-
oped an animal paradigm that combines RRS and
behaviorally effective, short-term antidepressant treat-
ment, followed by long-term high-fat diet. This mimics
a clinical situation experienced by millions of people:
stress/depression is associated with short-term expo-
sure to antidepressants and with long-term ingestion
of high-fat diets. In such a paradigm, we tested the
specific hypothesis that even short-term exposure to
antidepressants represents a long-term risk factor for
obesity, manifested protractedly when unmasked by
environmental factors, such as high-fat diet.
Materials and methods
Animals
All procedures were performed under established
guidelines of humane care and use of rats, and
were approved by the University of Miami Institu-
tional Animal Care and Use Committee, and by the
Australian National University Ethics Committee.
Upon arrival, virus- and antibody-free young adult
male Sprague-Dawley rats (Harlan, Indianapolis, IN,
USA) were housed at 241C and 12h light/dark
schedule (lights on from 0600 to 1800h) in a stress-
free environment and divided into two studies:
(1) chronic antidepressant treatment and (2) stress,
antidepressant and diet (hereafter, stress-antidepres-
sant-diet study).
Chronic antidepressant treatment study
Young growing rats (150–200g) were housed two per
cage in a stress-free environment for at least 5 days
before the initiation of experimental procedures. Rats
were randomly assigned to two experimental groups:
control (0.9% saline; Hospira, Lake Forest, IL, USA),
n=10 and fluoxetine 10mg (SSRI, Sigma-Aldrich,
St Louis, MO, USA), n=10. Animals received daily
0.5ml intraperitoneal injections of either 0.9% saline
or fluoxetine 10.0mgkg
–1 dissolved in 0.9% saline,
for 5 weeks. Dose and treatment duration were based
on previous reports.
19–21 BW was measured weekly.
Stress-antidepressant-diet study
Rats (200–230g) were housed one per cage
(11@ wide8.5@ height14.5@ long). Food intake
(FI) and BW were measured several times a week
starting one day after arrival (experimental day 1).
Rats were given ad libitum access to food and water,
except during the RRS sessions. This experiment
lasted 177 days.
Rats were randomly assigned to two main groups:
(1) non-restrained control (non-RRS) group (n=26)
and (2) restrained (RRS) group (n=38). Animals in
the non-RRS group were not injected or restrained,
and this group comprised two subgroups: (i) NR-CC
(n=13), comprising non-RRS animals fed with
regular chow diet throughout the whole experiment;
and (ii) NR-CF (n=13), comprising non-RRS animals
fed with chow diet until day 11, and fed with
adjusted fat diet thereafter (TD95217; Harlan, Saint
Louis, MO, USA).
Animals in the RRS group were subjected to RRS
as described below, and received adjusted fat diet
(TD95217; Harlan) after day 11. The RSS group
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comprising RRS animals that received once daily
intraperitoneal injection of 0.5ml of saline (0.9%
NaCl; Hospira); and (ii) R-AD group (n=25), compris-
ing RRS plus antidepressant-treated animals receiv-
ing daily intraperitoneal injection of antidepressants
for 7 days during the RRS period. Those animals
received imipramine (Sigma-Aldrich) 10mgkg
–1 (R-
IMI, n=13) or fluoxetine (Sigma-Aldrich) 10mgkg
–1
(R-FLX, n=12).
Repeated restraint stress. We used flat-bottom clear
acrylic restrainers (20.38.3cm) (Cat no. 544-RR;
Plas Labs, Lansing, MI, USA). RRS sessions
occurred during the period of 0900 to 1600h and
lasted 6h each; they occurred for 7 consecutive days
(days 5–11).
BW and FI. During the RRS period, BW and FI were
measured daily in all animals; BW gain was
calculated as the area under the BW curve for non-
RRS (n=26) or RSS (n=38) groups between days 5
and 11 (Figure 2b). After the restraining period, BW
and FI were recorded three times per week until the
end of the study at day 177.
Determination of absolute cumulative caloric
intake: FI was assessed by calculating the weight
difference of the food pellets remaining on the cage
top between two consecutive determinations. The
amount of food consumed was multiplied by its
respective caloric content (3.36kcalg
–1 for the regular
chow and 4.3kcalg
–1 for the adjusted fat diet). The
mean cumulative caloric intake was calculated sepa-
rated for the restraint period for the non-RRS and
the RRS groups. The cumulative intake during the
post-restraint period (between days 12 and 177)
was plotted as a function of time for the two major
restrained groups, namely R-C and R-AD.
Daily caloric intake: Daily caloric intake was
calculated between days 133 and 163, a period
including a total of 14 periods. Individual FI incre-
ments were converted into daily caloric intake by
dividing the total amount of calories determined
between two consecutive measurements by the day
interval (2 or 3 days). These individual caloric intake
values were averaged for each period for each
experimental group (R-C and R-AD).
Linear growth, fat mass and behavior. Body and bone
length and locomotor activity were determined in a
subset of rats (R-C, n=5; R-IMI, n=5; and R-FXT,
n=4).
Body measurements: Ano-nasal length was deter-
mined weekly (four times) between days 133 and 150.
Bone measurements: At the end of the study (day
177), rats were euthanized and their left hind legs
were also dissected and heated for 2h at 801Ci na
solution containing 3ml ammonia solution (7N in
methanol) and 25ml of water to facilitate bone
dissection. Lengths of dissected femurs and tibias
were measured with a caliper.
Fat mass: At the end of the study (day 177), rats
were euthanized and epididymal fat pads were
dissected and their fresh weights were obtained.
Locomotor activity: During the post-restraint period
(14–67 days), a subset of rats (R-C, n=5 and R-AD,
n=9) was submitted to 7 weekly 60min open field
test sessions (between 1400 and 1600h). Animals
were individually placed in clear acrylic boxes
(40.6440.64cm) equipped with Digiscan activity
monitors (Omnitech Electronics, Columbus, OH,
USA) with infrared light-sensitive detectors situated
2.5cm apart on two perpendicular walls. Located
along the opposing wall were infrared light beams
directed at the detectors. One count of horizontal
activity was registered each time the animal inter-
cepted the beam. The total distance (TD) was obtained
as horizontal activity counts and the center distance
(CD) was obtained as horizontal activity counts in the
center of the box. In each session, TD, CD and the
ratio CD/TD, used as an index of anxiety, were
calculated for the R-C and the R-AD groups. Their
means were subsequently averaged along the seven
sessions.
Statistical analysis
Differences among X3 groups were analyzed by one-
way analysis of variance followed by the Student–
Neuman–Keuls multiple comparison test for unequal
replications. Differences between two groups were
analyzed by ‘t’ test or Mann–Whitney test when
appropriate. The significance level for each of these
effects was set at P<0.05. All statistical analyses were
performed using GraphPad Prism 5.00 (GraphPad
Software, La Jolla, CA, USA).
Results
Effects of chronic antidepressant treatment on BW
Stress-free animals receiving regular chow and treated
with chronic administration of fluoxetine 10mgkg
–1
for 5 weeks had lower weight when compared with
animals treated with saline (mean±s.e., 336.7±3.8g
for saline and 312.0±3.7g for fluoxetine, P<0.0001).
Effects of stress-antidepressant-diet paradigm
Figure 1a shows BW changes for all the five groups
during the entire duration of the stress-antidepres-
sant-diet study.
Acute effects of RRS. RRS sessions were performed
for 7 consecutive days (days 5–11); during the RRS
sessions, rats that were submitted to RRS ingested less
calories (mean±s.e., 672.6±9.5 and 753.1±15.7kcal,
respectively, for RRS and non-RRS groups, P<0.0001,
Figure 2a) and gained significantly less weight
(1486.0±6.4gday for RSS and 1592.0±13.5g
day for non-RSS, P<0.0001, Figure 2b) when
compared with control non-stressed animals.
Fat diet. Adjusted fat diet was initiated on study day
11 and caused non-stressed animals (NR-CF) to
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(NR-CC) (503.0±8.5 and 477.4±6.5g, respectively,
P=0.025).
Post-stress recovery period. In the immediate post-
stress period, stressed and non-stressed animals fed
with high-fat diet had similar absolute caloric intake.
RSS animals that received saline (R-C) and fed with
high-fat diet achieved full weight recovery, and their
weights at day 26 were not significantly different from
those of non-stressed animals (NR-CF) receiving fat
diet (328.0±2.7 and 336.8±4.8g, respectively, P=0.1).
Late in the post-stress recovery period (133–163 days),
antidepressant-treated rats (R-AD) became heavier than
R-C (Figure 1b, 498.0±2.71g for R-FXT, 490.4±3.06g
for R-IMI and 477.8±2.85g for R-C, P<0.001forR-FXT
and R-C; and P<0.01 for R-IMI and R-C) and had
significantly higher caloric intake when compared with
the R-C group (Figures 3a and b, 70.9±1.3 for R-AD and
66.0±1.0 for R-C, P=0.006). During this period both
R-AD and R-C groups were fed with high-fat diet.
Linear growth, fat mass and behavior.
Linear growth: Compared with the non-treated RSS
animals, antidepressant-treated RRS animals had
larger body size (Figure 3c, 27.3±0.2cm for R-AD
(n=9) and 26.0±0.4cm for R-C (n=5), P=0.009),
longer femur (Figure 3d, 4.2±0.01cm for R-AD and
4.1±0.03cm for R-C, P=0.01) and tibia (Figure 3e,
4.5±0.02cm for R-AD and 4.4±0.03cm for R-C,
P=0.004).
Epididymal fat pad measurements: As expected, fat
diet increased total body fat content as measured by
the fresh weight of epididymal fat pads (12.6±0.7g
for NR-FC and 7.4±1.0g for NR-CC, P=0.001) and
epididymal fat pad/BW ratios (23.3±0.910
–3 for
NR-FC and 14.9±1.810
–3 for NR-CC, P=0.0003),
but these parameters were not significantly different
between stressed and non-stressed animals (12.8±
0.7g for RRS and 11.9±1.7g for non-RRS, P=0.53;
23.4±0.910
–3 for RRS and 22.8±2.410
–3 for
non-RRS, P=0.8).
Locomotor Activity: A subset of antidepressant-
treated animals was tested for locomotor activity and
they showed higher locomotor activity reflected both
as TD (Figure 4a, 4011.0±187.4cm for R-AD and
2824.0±324.7cm for R-C, P=0.003) and CD (Figure
4b, 1375.0±58.8cm for R-AD and 779.9±66.3cm for
R-C, P<0.0001), and the ratio CD/TD suggests that
RSS animals treated with antidepressants were less
anxious in the open field test in comparison with
non-treated RRS animals (Figure 4c, 0.4±0.01 for R-
AD and 0.3±0.01 for R-C, P=0.004).
Discussion
We show here that during the course of a stress
paradigm (restraint), short-term exposure to antide-
pressants decreases the depressive and anxiety
behavioral correlates of stress. However, that short
exposure to antidepressants is associated with
Figure 2 Interactions of recurrent restraint stress (RRS) and
short-term antidepressant treatment on food intake and body
weight during the RRS sessions. (a) Cumulative absolute
intake (kcal) during the restraint stress (days 5–11) period in
non-RRS (n=26) and RRS rats (n=38); during this period, all
animals were fed with regular chow. Non-RRS consumed a
larger amount of kcal. (b) Body weight gain was calculated by
obtaining the area under the weight curve (AUC, gday)
during the restraining period. Non-RRS animals were heavier
than RRS ones. ***P<0.0001.
Figure 1 Body weight (BW) in grams during the experi-
mental period. (a) BW was measured during days 1–177 of
our stress-antidepressant-diet study. The small black bar
above the x axis indicates the recurrent restraint stress (RRS)
period, 6hday
–1 during 1 week. Dots represent mean BW at
each particular day. NR-CC, non-restraint control on regular
diet group (n=13); NR-CF, non-restraint control on fat diet
group (n=13); R-C, untreated RRS on fat diet group (n=13);
R-IMI, imipramine-treated RRS on fat diet group (n=13);
R-FXT, fluoxetine-treated RRS on fat diet group (n=12). The
inset (b) depicts the average BW of the three experimental
groups subjected to RRS and fed with high-fat diet during
the post-restraint period. Columns and bars depict mean and
the s.e.m., respectively. Antidepressant treated groups were
compared to control R-C group. **P<0.01; ***P<0.001.
Long-term BW outcomes of antidepressant–environment interactions
C Mastronardi et al
268
Molecular Psychiatrysignificant body size and weight gain 122 days after
discontinuation of antidepressant treatment in the
context of a high-fat diet. We also show that a high-fat
diet leads to correction of stress-induced weight loss
in the absence of antidepressant treatment. These data
suggest that exposure to antidepressants is a long-
term risk factor for weight gain and obesity, even
after antidepressant treatment is discontinued for a
long time.
The relationship of antidepressant treatment and
weight gain needs to be carefully examined. Clini-
cally, weight gain is a common occurrence during
both acute and long-term treatment with antidepres-
sants,
22 and it is a major problem for two reasons:
(1) depressed patients are already at increased risk of
cardiovascular disease,
23 and weight gain could
worsen that risk; and (2) weight gain is a cause
of decreased antidepressant treatment compliance,
resulting in treatment dropout.
24 In adults, pooled
analyses showed that SSRI treatment induces
short-term weight loss, but long-term weight gain.
25
There is still controversy of whether weight gain is
mechanistically related to clinical improvement or if
it is merely an undesirable side effect of antidepres-
Figure 3 Interactions of recurrent restraint stress (RRS), short-term antidepressant treatment and fat diet on caloric intake,
body weight and bone length. (a) Cumulative absolute intake (kcal10
3) during post-restraint stress (days 12–177). Late in
the post-stress recovery period (starting on day 133 or 4.4 months), antidepressant-treated animals had significantly higher
caloric intake when compared with non-treated RRS animals (R-C, n=13; R-AD, n=25). Inset (b) shows the average of daily
caloric intake (days 133–163) for 14 periods. (c) Body length (cm) at day 150; R-C, n=5; R-AD, n=9. Antidepressant-treated
RRS had larger bodies. (d) Femur length (cm) was obtained at end of the experiment, day 177. Antidepressant-treated RRS
animals had longer femurs. (e) Tibia length was obtained at day 177. Antidepressant-treated RRS animals had longer tibias.
*P<0.05; **P<0.01.
Figure 4 Interactions of recurrent restraint stress (RRS), short-term antidepressant treatment and fat diet on locomotor
activity and anxiety. Open field tests were conducted after the period of RRS ended, each session lasted 60min from days 14
to 67. (a) RRS-antidepressant treated group (R-AD) had increased total distance (TD) when compared with untreated RRS
animals (R-C). (b) R-AD group had increased center distance (CD) when compared with R-C. (c) Anxiety was estimated by the
ratio of center distance (CD) over TD; R-AD animals were significantly less anxious than R-C. Columns and bars (a–c) depict
mean and s.e., respectively; **P<0.01; ***P<0.0001.
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22 Weight data have been derived
primarily from re-analysis of drug trials or cross-
sectional observation data.
26,27 Moreover, it appears
that specific types of antidepressants, such as tricyc-
lic antidepressants and mirtazapine, are more likely
to induce weight gain.
28
Our data suggest that antidepressant treatment has
a complex effect on BW regulation dependent on
environmental factors. Under standard laboratory
conditions and diet, non-stressed rats receiving
chronic fluoxetine treatment weighed less than
saline-treated controls, which is compatible with the
literature.
15 In our stress-antidepressant-diet study,
animals submitted to RRS consumed fewer calories
and were lighter during the stress period.
What is reported here as a novel finding is that
animals that were given fat diet after the stress
period ended achieved full weight recovery: the
weights of non-treated animals (R-C, saline control
group) were not significantly different from those of
non-stressed animals receiving fat diet (NR-CF). In
contrast, non-treated rats receiving regular chow
might not recover restraint-induced weight loss.
29
RSS animals that received antidepressant treatment
(R-AD) had behavioral manifestations of antidepres-
sant action, as documented by decreased behavior
that is attributable to stress and anxiety in open field.
Our most noteworthy and novel finding was that
when the combination of stress and short-term
antidepressant treatment was followed by long-term
high-fat diet after antidepressants were discontinued
(Figures 1a and b), animals gained more weight when
compared with rats submitted to the same paradigm
but never exposed to antidepressants (R-C). As our
open field data do not support a reduction of
locomotor activity in the group exposed to antide-
pressants (Figure 4), the small but significant weight
increase in those animals can be explained by their
small but significantly higher caloric intake when
compared with stressed animals not exposed to
antidepressants.
Weight gain in the post-stress period is related to
recovery of sympathetic function and hypothalamus–
pituitary–adrenal axis activation.
30,31 Our data sup-
port the notion that the interaction of short-term
antidepressant treatment during acute stress, and
high-fat diet during long-term recovery, may potenti-
ate the mechanisms underlying post-stress weight
recovery and result in small but significant increases
in FI and BW. Therefore, our results indicate
that passage of time constitutes a key factor for the
effects of antidepressants in weight regulation. This
phenomenon is in agreement with the concept of
TDS described in detail by Antelman et al.
18,32–34
Their studies demonstrate that antidepressant- or
electroconvulsive shock-induced effects grow with
the passage of time.
35 For instance, a single electro-
convulsive shock reduced dopamine autoreceptor
sensitivity by 85% in the central nervous system
after 1 week, but not after 1h.
35 Furthermore, six
daily electroconvulsive shocks produced a similar
magnitude of inhibition after 1 week of the initial
intervention as that displayed by a single electro-
convulsive shock.
35 Similar results were also
achieved by the administration of tricyclic antide-
pressants such as imipramine and amitriptyline.
35
The results of that body of work suggest that the
observed delay in the therapeutic effects of antide-
pressant occurred as a consequence of the biological
changes triggered by the initial treatment rather than
pharmacokinetics factors elicited by daily chronic
drug administration.
35 It is plausible that the concept
of TDS may be applied to the pharmacological effects
of antidepressants in weight regulation, which would
result in long-term increases in caloric intake and BW
gain. We hypothesize that the mechanism of action for
TDS might require epigenetic modifications.
This study suggests that the ‘paradoxical’ effect of
antidepressant treatment in BW in humans when
compared with rodents may be explained by the
simplified experimental paradigm generally used in
rodents, which has not accounted for environmental
factors, such as stress and diet, or a meaningfully long
follow-up period. We show here that the inclusion of
environmental factors after antidepressant treatment
may induce long-term weight gain in rodents; there-
fore, the default explanation that differences in
metabolic and neuroendocrine pathways regulating
appetite and energy metabolism are required to
explain the discrepancy of antidepressant effects in
BW between human and rodents
14 needs to be
revisited, and as such differences may in reality be
small or non-existent.
Given that noncompliance to antidepressant
treatment seems to be high in the general population
(>50%),
13 our data emphasize the need to examine
whether these drugs have effects on BW regulation
that persist on a long-term basis after their disconti-
nuation. Alarmingly, SSRI drugs have become so
popular that they are already been called ‘lifestyle’
drugs.
36,37 In the United States, obesity rates started
to increase markedly in the late 1980s, which
coincides temporally with the introduction of SSRIs.
Yearly increases in the rates of antidepressant
dispensing
7 seem to parallel increases in obesity
rates;
38 however, detailed analyses of those trends at
the population level are required to establish a
clinical association.
In conclusion, we propose here that antidepressant
treatment, occurring in the context of conditions of
high stress and high-fat intake, might be a covert,
insidious and long-lasting contributor to weight gain,
even after antidepressant drugs are discontinued for a
long time, which is compatible with the phenomenon
of TDS. Further research is needed to understand the
pathways and pathophysiological mechanisms in-
volved in pharmacological–environment interactions
underlying the protracted effects of antidepressant
drugs on caloric intake and body size and weight.
Future studies should also address the role of stress
and high-fat diets on long-term BW outcomes during
and following antidepressant treatment in clinical
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stand whether long-term BW gain also occurs in
animals fed with a variety of different diets, following
exposure to stress and time-limited antidepressant
treatment.
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